Drug Database
Back to search

France· FR:69326436

ENSPRYNG 120 mg, solution injectable en seringue préremplie

A satralizumab product containing satralizumab, registered in France by ROCHE REGISTRATION (ALLEMAGNE), on the national reimbursement list. The same ATC class is registered in 13 of our 19 countries.

Reimbursed in France (Assurance maladie)ATC L04AC19

Checked against Base de données publique des médicaments — BDPM (France) on

Informational only — not a medical device.

SOURCE REGISTER · FRBase de données publique des médicament…normalisedENSPRYNG 120 mg, solution injectable …ATCL04AC19REGISTER NO.FR:69326436PACKS LISTED1CHECKEDSeptember 12, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about satralizumabAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Satralizumab is registered in 13 of 19 countries.

Countries holding a registration under ATC L04AC19 (satralizumab), each read from that country’s own register.

  • This record: France, from Base de données publique des médicaments — BDPM (France)
  • 8 of them publish a price we can compare per daily dose
Search satralizumab products by name

Satralizumab · ATC L04AC19

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Base de données publique des médicaments — BDPM (France)
Active substance
SATRALIZUMAB
Manufacturer
ROCHE REGISTRATION (ALLEMAGNE)
Country
France (FR)
ATC code
L04AC19
ATC class
Satralizumab
Defined daily dose
4.3 mg, P
Reimbursed
Yes
Source register
Base de données publique des médicaments — BDPM (France)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • cip13
    3400930234433
    1 seringue(s) préremplie(s) poly(ferrocénylsilane) (PFS) de 1 ml
    EUR 7.56

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

115 interactions on record for satralizumab.

Graded by severity as the source publishes them — 35 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check satralizumab against other medicinesHow interaction checks work

Satralizumab · interactions on record

115 records

  • 35 severe
  • 74 moderate
  • 6 minor

Most severe, free to view

  • CladribineL01BB04severe
  • RituximabL01FA01severe
  • RituximabL01XC02severe
  • Talimogene laherparepvecL01XL02severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Satralizumab in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All satralizumab products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Enspryng, Enspryng Pre-Filled Pen Pre-Filled Pen
  • Liechtenstein · Enspryng, Enspryng Pre-Filled Pen Pre-Filled Pen
  • Norway · Enspryng, Enspryng Pre-Filled Pen Pre-Filled Pen

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/e00d7e90-9473-4ad8-b5d1-9a9ac62105ab
GET /v1/drugs/e00d7e90-9473-4ad8-b5d1-9a9ac62105ab?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cis": "69326436",
  "date_amm": "2021-06-24",
  "type_amm": "Procédure centralisée",
  "numero_ue": "EU/1/21/1559",
  "substance": "SATRALIZUMAB",
  "atc_source": "fr_atc_restore_2026-09-06",
  "statut_amm": "Autorisation active",
  "statut_bdm": null,
  "forme_pharmaceutique": "solution injectable",
  "voies_administration": "sous-cutanée",
  "etat_commercialisation": "Commercialisée",
  "surveillance_renforcee": "Non"
}
API referenceMCP serverPlans

See everything about satralizumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console